Sign in
Taking people in United StatesPhase 2

Testing Drug Treatments After CAR T-cell Therapy for Lymphoma

Tests mosunetuzumab or polatuzumab vedotin in adults with lymphoma returning after CAR T-cell therapy.

Key facts

Who runs it
SWOG Cancer Research Network
Where
Albuquerque, Atlanta, Baltimore, Baton Rouge, Battle Creek, Boiling Springs, Boise, Burlington, Charleston, Charlotte, Chicago, Cleveland, Clinton Township, Concord, Costa Mesa, Danville, Dearborn, Detroit, Durham, Easley, Fargo, Farmington Hills, Fayetteville, Fruitland, Gainesville, Grand Rapids, Greenville, Greer, Iowa City, Irvine, Jackson, Kalamazoo, Kansas City, Laguna Hills, Lebanon, Little Rock, Louisville, Madison, Maywood, Memphis, Meridian, Milwaukee, Muskegon, Nampa, New Berlin, New York, Newberg, Niles, Norton Shores, Novi, Oklahoma City, Orange, Oregon City, Overland Park, Philadelphia, Portland, Reed City, Richmond, Rochester, Rogers, Saint Johnsbury, Saint Joseph, San Francisco, Seattle, Seneca, Southfield, Springdale, Traverse City, Tucson, Twin Falls, Webster, West Bloomfield, Westwood, Wilkes-Barre, Winston-Salem, Wyandotte, and Wyoming, United StatesSee the 95 sites
Trial code
Registry title
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status
Recruiting
Phase
Phase 2
People taking part
396 people, planned
Started
12 Jun 2023
Expected to end
30 Jun 2030
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Axicabtagene Ciloleucel
  • Biospecimen Collection
  • Computed Tomography
  • Cyclophosphamide
  • Fludarabine
  • Lisocabtagene Maraleucel
  • Mosunetuzumab
  • Patient Observation
  • Polatuzumab Vedotin
  • Positron Emission Tomography
  • Tisagenlecleucel
Record updated
15 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diffuse large B-cell lymphoma, grade 3b follicular lymphoma or primary mediastinal large B-cell lymphoma who plan to receive commercial CD19 CAR T-cell therapy. Drugs are tested after CAR T.

Age
18 years or older
Sex
All sexes can join
Disease stage
Diffuse large B-cell lymphoma, follicular lymphoma grade 3b or primary mediastinal large B-cell lymphoma, with disease that can be measured. Transformed lymphoma must come from follicular or marginal zone lymphoma. Brain or spinal involvement must cause no symptoms. After CAR T, a PET-CT scan on days 25-40 must show stable disease or partial remission.
Earlier treatment
Must be planned for commercial FDA-approved CD19 CAR T-cell therapy. Bridging therapy is allowed, but not with polatuzumab vedotin or mosunetuzumab. Earlier polatuzumab vedotin or mosunetuzumab is allowed only if there was no relapse or progression within 6 months of the last dose.

Main reasons for not taking part

  • Complete remission on the scan after bridging therapy
  • Polatuzumab vedotin or mosunetuzumab given as bridging therapy
  • CAR T-cell product that does not meet the standards for a commercial product
  • Peripheral neuropathy of grade 2 or worse
  • Heart ejection fraction below 40%

The registry criteria, word for word

Show all 55 criteriaShow less

Who can take part

  • STEP 1: REGISTRATION: Participants must have a histologically confirmed diagnosis of diffuse large B-cell lymphoma or follicular lymphoma grade 3b or primary mediastinal large B-cell lymphoma (PMBCL)
  • STEP 1: REGISTRATION: Participants with transformed DLBCL must have transformed DLBCL from follicular or marginal zone lymphoma
  • STEP 1: REGISTRATION: Participant must have bi-dimensionally measurable systemic disease (at least one lesion with longest diameter > 1.5 cm)
  • STEP 1: REGISTRATION: Participants with secondary central nervous system (CNS) lymphoma (parenchymal, spinal cord, meningeal, cerebrospinal fluid involvement) must be asymptomatic from their CNS disease
  • STEP 1: REGISTRATION: Participants must be registered for step 1 after they have signed institutional consent for CAR T-cell leukapheresis but prior to the start of lymphodepleting (LD) chemotherapy for commercial CAR T-cell product
  • STEP 1: REGISTRATION: In the opinion of the enrolling physician, participants must be felt to be a candidate for CAR T-cell therapy with plans to be treated with Food and Drug Administration (FDA) approved commercially available CD19 CAR T-cell construct; Participants must qualify for commercially approved CD19 CAR T-cell therapy per FDA package insert; If the CAR T-cell product does not meet parameters to be given as an FDA approved product (i.e. does not meet specification criteria mandated by FDA and is infused under an expanded access protocol [EAP] or single participant investigational new drug [IND]) the participant will be taken off of study and no longer be eligible for step 2 randomization
  • STEP 1: REGISTRATION: Participants are permitted to receive or have received 'bridging therapy' after CAR T-cell leukapheresis. However, participants must not receive polatuzumab vedotin, and/or mosunetuzumab as part of bridging therapy; Bridging therapy is defined as lymphoma directed therapy administered between leukapheresis and the start of LD chemotherapy. This includes cytotoxic chemotherapy (e.g.: bendamustine and rituximab [BR], rituximab, gemcitabine and oxaliplatin [R-gem/ox]), radiation, corticosteroids, as well as novel therapies such as BTK inhibitors (e.g.: Ibrutinib), immunomodulators (e.g.: lenalidomide), monoclonal antibodies (e.g.: rituximab, obinutuzumab, tafasitamab) antibody drug conjugates (e.g: loncastuximab), checkpoint inhibitors (e.g.: pembrolizumab, nivolumab), clinical trial treatments, etc; If a participant receives polatuzumab vedotin or mosunetuzumab as bridging they will ineligible to continue on step 1 registration portion of the study and be ineligible for step 2 randomization
  • STEP 1: REGISTRATION: PET-CT scan must be planned for completion within 60 days prior to the start of LD chemotherapy; All pre-CAR T-cell therapy disease must be assessed and documented on the baseline/pre-registration tumor assessment form; If receiving bridging therapy, participants must have a PET-CT scan upon completion of all planned bridging therapy. If the PET-CT scan after completion of bridging therapy is consistent with complete remission per Lugano criteria as determined by enrolling physician, that participant will be ineligible for step 2 randomization; Participants are permitted to receive corticosteroids after leukapheresis without the need to repeat a PET-CT scan. If steroids are used, they must be planned to stop no later than 3 days before CAR -T cell infusion; If response assessment by central review cannot be completed (I.e., poor quality of PET-CT scan, PET-CT performed out of window, etc.) this would be recorded as 'inadequate assessment' and patient would not be eligible for randomization
  • STEP 1: REGISTRATION: Participants that have previously been treated with polatuzumab vedotin or mosunetuzumab prior to CAR T-cell leukapheresis for either indolent or aggressive NHL are eligible as long as the participant did not have refractory disease or progression/relapse within 6 months of the last infusion with either agent
  • STEP 1: REGISTRATION: Participants must be planning to receive CAR T-cell infusion no earlier than 2 days and no later than 14 days after completion of the last day of lymphodepleting chemotherapy. Any participant receiving CAR T-cell infusion outside of this window will be ineligible for step 2 randomization
  • STEP 1: REGISTRATION: LD chemotherapy prior to CAR T-cell infusion must be planned to start within 60 days after step 1 registration
  • STEP 1: REGISTRATION: Participants must be >= 18 years of age at the time of registration
  • STEP 1: REGISTRATION: Participants must have Zubrod performance score (PS) of 0, 1, or 2
  • STEP 1: REGISTRATION: Total bilirubin =< 2 x institutional upper limit of normal (ULN) (within 14 days prior to registration); Unless due to Gilbert's disease or lymphomatous involvement of liver
  • STEP 1: REGISTRATION: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional ULN (within 14 days prior to registration)
  • STEP 1: REGISTRATION: Creatinine clearance >= 40 mL/min, as estimated by the Cockcroft and Gault formula. The creatinine value used in the calculation must have been obtained within 14 days prior to registration. Estimated creatinine clearance is based on actual body weight
  • STEP 1: REGISTRATION: Participants must have an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 60 days prior to registration with a cardiac ejection fraction >= 40%; Participants with current symptoms of cardiac disease must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better; Participants must not have documented myocardial infarction and percutaneous coronary intervention (PCI) within 6 months prior to registration or myocardial infarction without PCI within 3 months of registration, or unstable angina
  • STEP 1: REGISTRATION: Participants with peripheral neuropathy must have < grade 2
  • STEP 1: REGISTRATION: Participants with hepatitis B virus infection must have undetectable viral load within 14 days prior to registration, be on suppressive therapy and have no evidence of hepatitis B virus (HBV) related hepatic damage
  • STEP 1: REGISTRATION: Participants with hepatitis C infection must have eradication therapy completed, have no evidence of hepatitis C infection (HCV) related damage and have undetectable viral load within 14 days prior to registration
  • STEP 1: REGISTRATION: Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration
  • STEP 1: REGISTRATION: Participants must be offered the opportunity to participate in banking for planned translational medicine and future research. With participant consent, any residuals from the mandatory tissue submission will also be banked for future research; Note: Streck tubes must be ordered in advance. Please allow 5-7 days for shipment of the collection kits
  • STEP 1: REGISTRATION: NOTE: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system; Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines; For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
  • STEP 2: RANDOMIZATION: Participants must have met all eligibility criteria for step 1 registration
  • STEP 2: RANDOMIZATION: Participant's CAR T-cell product must have met specification parameters to be given as an FDA approved commercial product
  • STEP 2: RANDOMIZATION: Participants must have a PET-CT scan between days 25-40 after CAR T-cell infusion and determined to have a response consistent with stable disease or partial remission by central review compared to most recent pre-LD chemo/CAR T-cell PET-CT scan; Note: Patients with delayed enrollment > 21 days after 'day +30' PET-CT scan will necessitate a repeat PET-CT scan if concerning signs or symptoms of lymphoma progression develop; Note: If response assessment by central review cannot be completed (I.e., poor quality of PET-CT scan, PET-CT performed out of window, etc.) this would be recorded as 'inadequate assessment' and patient would not be eligible for randomization
  • STEP 2: RANDOMIZATION: Eligible participants must be randomized no later than 60 days after CAR -T infusion
  • STEP 2: RANDOMIZATION: Participants must have started LD chemotherapy within 60 days of signing consent for step 1 registration
  • STEP 2: RANDOMIZATION: Participants must have S2114 CAR T-cell therapy form submitted to Southwest Oncology Group (SWOG) prior to step 2 randomization
  • STEP 2: RANDOMIZATION: Participants must have had a PET-CT scan upon completion of all planned bridging therapy if received, with the exception of up to 7 days of corticosteroids. If the PET-CT scan after completion of bridging therapy was consistent with complete remission per Lugano criteria as determined by enrolling physician, that participant will be ineligible for step 2 randomization; If response assessment by central review cannot be completed (I.e., poor quality of PET-CT scan, PET-CT performed out of window, etc.) this would be recorded as 'inadequate assessment' and patient would not be eligible for randomization
  • STEP 2: RANDOMIZATION: Participants must have Zubrod PS of 0, 1, or 2
  • STEP 2: RANDOMIZATION: Absolute neutrophil count (ANC) >= 1.0 x 10\^3/uL and participants must not have received myeloid growth factor within 72 hours prior to this lab being drawn (within 7 days prior to step 2 randomization)
  • STEP 2: RANDOMIZATION: Platelets >= 75 x 10\^3/uL and participants must not have received platelet transfusion within 72 hours prior to this lab being drawn (within 7 days prior to step 2 randomization)
  • STEP 2: RANDOMIZATION: Total bilirubin =< 2 x institutional ULN (within 7 days prior to step 2 randomization); Unless due to Gilbert's disease or lymphomatous involvement of liver
  • STEP 2: RANDOMIZATION: AST and ALT =< 3 x institutional ULN (within 7 days prior to step 2 randomization)
  • STEP 2: RANDOMIZATION: Creatinine clearance >= 40 mL/min, as estimated by the Cockcroft and Gault formula. The creatinine value used in the calculation must have been obtained within 7 days prior to step 2 randomization. Estimated creatinine clearance is based on actual body weight (within 7 days prior to step 2 randomization)
  • STEP 2: RANDOMIZATION: Participants with peripheral neuropathy must have < grade 2
  • STEP 2: RANDOMIZATION: Participants with current symptoms of cardiac disease must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
  • STEP 2: RANDOMIZATION: Participants with history of hepatitis B viral infection must have undetectable viral load within 14 days prior to step 2 randomization and on suppressive therapy
  • STEP 2: RANDOMIZATION: Participants with history of hepatitis C viral infection must have undetectable viral load within 14 days prior to step 2 randomization
  • STEP 2: RANDOMIZATION: Participants with known human immunodeficiency virus (HIV)-infection must be continuing to receive anti-retroviral therapy and have an undetectable viral load test within 14 days prior to step 2 randomization
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants must have documented disease progression while on Arm 4 (observation) on this protocol. The follow-up tumor assessment form documenting disease progression must be submitted to SWOG prior to step 3 crossover registration
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants must be registered within 28 days of the date of progression
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants must have imaging that clearly demonstrates progression compared to day +30 PET-CT scan; Note: These scans should be performed as standard of care and only performed between scheduled response assessments required for study if symptoms arise that are concerning for progression
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants must have Zubrod PS of 0, 1, or 2
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): ANC >= 1.0 x 10\^3/uL and participants must not have received myeloid growth factor within 72 hours prior to this lab being drawn (within 14 days prior to step 3 crossover registration)
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Platelets >= 75 x 10\^3/uL and participants must not have received platelet transfusion within 72 hours prior to this lab being drawn (within 14 days prior to step 3 crossover registration)
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Total bilirubin =< 2 x institutional ULN (within 14 days prior to step 3 crossover registration); Unless due to Gilbert's disease or lymphomatous involvement of liver
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): AST and ALT =< 3 x institutional ULN
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Creatinine clearance >= 40 mL/min, as estimated by the Cockcroft and Gault formula. The creatinine value used in the calculation must have been obtained within days prior to step 3 crossover registration. Estimated creatinine clearance is based on actual body weight (within 14 days prior to step 3 crossover registration)
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants with peripheral neuropathy must have < grade 2
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants with current symptoms of cardiac disease must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants with history of hepatitis B viral infection must have undetectable viral load within 14 days prior to step 3 crossover registration and on suppressive therapy
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants with history of hepatitis C viral infection must have undetectable viral load within 14 days prior to step 3 crossover registration
  • STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants with known human immunodefici

Where in United States

  • University of New Mexico Cancer CenterAlbuquerque, United StatesContact: Erin RogersNo longer taking part
  • Emory Saint Joseph's HospitalAtlanta, United StatesContact: Kristie A. Blum (principal investigator)Taking people
  • Emory University Hospital/Winship Cancer InstituteAtlanta, United StatesContact: Kristie A. Blum (principal investigator)Taking people
  • Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, United StatesContact: Cole H. Sterling (principal investigator)Taking people
  • University of Maryland/Greenebaum Cancer CenterBaltimore, United StatesContact: Jean A. Yared (principal investigator)Taking people
  • LSU Health Baton Rouge-North ClinicBaton Rouge, United StatesContact: Nakhle S. Saba (principal investigator)Taking people
  • Our Lady of the Lake Physician GroupBaton Rouge, United StatesContact: Nakhle S. Saba (principal investigator)Taking people
  • Bronson Battle CreekBattle Creek, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Prisma Health Cancer Institute - SpartanburgBoiling Springs, United StatesContact: Suzanne R. Fanning (principal investigator)Taking people
  • Saint Luke's Cancer Institute - BoiseBoise, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • University of Vermont and State Agricultural CollegeBurlington, United StatesContact: James N. Gerson (principal investigator)Taking people
  • University of Vermont Medical CenterBurlington, United StatesContact: James N. Gerson (principal investigator)Taking people
  • Medical University of South CarolinaCharleston, United StatesContact: Brian T. Hess (principal investigator)Taking people
  • Carolinas Medical Center/Levine Cancer InstituteCharlotte, United StatesContact: Nilanjan Ghosh (principal investigator)Taking people
  • University of Chicago Comprehensive Cancer CenterChicago, United StatesContact: Justin P. Kline (principal investigator)Taking people
  • University of IllinoisChicago, United StatesContact: Carlos Galvez (principal investigator)Taking people
  • Case Western Reserve UniversityCleveland, United StatesContact: Changchun Deng (principal investigator)Taking people
  • Henry Ford Macomb Hospital-Clinton TownshipClinton Township, United StatesContact: Philip Kuriakose (principal investigator)Taking people
  • Atrium Health Cabarrus/LCI-ConcordConcord, United StatesContact: Nilanjan Ghosh (principal investigator)Taking people
  • UC Irvine Health Cancer Center-NewportCosta Mesa, United StatesContact: Erin Dean (principal investigator)Taking people
  • Geisinger Medical CenterDanville, United StatesContact: Joseph P. Lynch (principal investigator)Taking people
  • Henry Ford Medical Center-FairlaneDearborn, United StatesContact: Philip Kuriakose (principal investigator)Taking people
  • Henry Ford HospitalDetroit, United StatesContact: Philip Kuriakose (principal investigator)Taking people
  • Wayne State University/Karmanos Cancer InstituteDetroit, United StatesContact: Joseph P. Uberti (principal investigator)Taking people
  • Duke University Medical CenterDurham, United StatesContact: Matthew S. McKinney (principal investigator)Taking people
  • Prisma Health Cancer Institute - EasleyEasley, United StatesContact: Suzanne R. Fanning (principal investigator)Taking people
  • Sanford Broadway Medical CenterFargo, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Sanford Roger Maris Cancer CenterFargo, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Weisberg Cancer Treatment CenterFarmington Hills, United StatesContact: Joseph P. Uberti (principal investigator)Taking people
  • Highlands Oncology Group - FayettevilleFayetteville, United StatesContact: Joseph T. Beck (principal investigator)Taking people
  • Saint Luke's Cancer Institute - FruitlandFruitland, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • UF Health Cancer Institute - GainesvilleGainesville, United StatesContact: Muhammad Junaid Tariq (principal investigator)Taking people
  • Corewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Trinity Health Grand Rapids HospitalGrand Rapids, United StatesContact: Erin RogersNo longer taking part
  • Prisma Health Cancer Institute - ButternutGreenville, United StatesContact: Suzanne R. Fanning (principal investigator)Taking people
  • Prisma Health Cancer Institute - EastsideGreenville, United StatesContact: Suzanne R. Fanning (principal investigator)Taking people
  • Prisma Health Cancer Institute - FarisGreenville, United StatesContact: Suzanne R. Fanning (principal investigator)Taking people
  • Prisma Health Cancer Institute - GreerGreer, United StatesContact: Suzanne R. Fanning (principal investigator)Taking people
  • University of Iowa/Holden Comprehensive Cancer CenterIowa City, United StatesContact: Eric Mou (principal investigator)Taking people
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, United StatesContact: Erin Dean (principal investigator)Taking people
  • Allegiance HealthJackson, United StatesContact: Philip Kuriakose (principal investigator)Taking people
  • Bronson Methodist HospitalKalamazoo, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • West Michigan Cancer CenterKalamazoo, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Beacon Kalamazoo Cancer CenterKalamazoo, United StatesContact: Erin RogersNo longer taking part
  • University of Kansas Cancer CenterKansas City, United StatesContact: Marc S. Hoffmann (principal investigator)Taking people
  • UCI Health - Laguna HillsLaguna Hills, United StatesContact: Erin Dean (principal investigator)Taking people
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon, United StatesContact: Charles Gaulin (principal investigator)Taking people
  • University of Arkansas for Medical SciencesLittle Rock, United StatesContact: Cesar Gentille (principal investigator)Taking people
  • The James Graham Brown Cancer Center at University of LouisvilleLouisville, United StatesContact: Hassaan Yasin (principal investigator)Taking people
  • UofL Health Medical Center NortheastLouisville, United StatesContact: Hassaan Yasin (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison, United StatesContact: Priyanka Pophali (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Priyanka Pophali (principal investigator)Taking people
  • Loyola University Medical CenterMaywood, United StatesContact: Imran Puthawala (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-MemphisMemphis, United StatesContact: Brion V. Randolph (principal investigator)Taking people
  • Saint Luke's Cancer Institute - MeridianMeridian, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • Medical College of WisconsinMilwaukee, United StatesContact: Mehdi Hamadani (principal investigator)Taking people
  • Trinity Health Muskegon HospitalMuskegon, United StatesContact: Erin RogersNo longer taking part
  • Saint Luke's Cancer Institute - NampaNampa, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • Froedtert and MCW Moorland Reserve Health CenterNew Berlin, United StatesContact: Mehdi Hamadani (principal investigator)Taking people
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, United StatesContact: Hua-Jay J. Cherng (principal investigator)Taking people
  • NYP/Weill Cornell Medical CenterNew York, United StatesContact: Gaurav Varma (principal investigator)Taking people
  • Providence Newberg Medical CenterNewberg, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • Corewell Health Lakeland Hospitals - Niles HospitalNiles, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Cancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores, United StatesContact: Erin RogersNo longer taking part
  • Henry Ford Medical Center-ColumbusNovi, United StatesContact: Philip Kuriakose (principal investigator)Taking people
  • University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Sami Ibrahimi (principal investigator)Taking people
  • UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, United StatesContact: Erin Dean (principal investigator)Taking people
  • Providence Willamette Falls Medical CenterOregon City, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • University of Kansas Cancer Center-Overland ParkOverland Park, United StatesContact: Marc S. Hoffmann (principal investigator)Taking people
  • University of Pennsylvania/Abramson Cancer CenterPhiladelphia, United StatesContact: Nasheed M. Hossain (principal investigator)Taking people
  • Oregon Health and Science UniversityPortland, United StatesContact: Andy I. Chen (principal investigator)Taking people
  • Providence Portland Medical CenterPortland, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • Providence Saint Vincent Medical CenterPortland, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • Corewell Health Reed City HospitalReed City, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: Sneha Purvey (principal investigator)Taking people
  • University of RochesterRochester, United StatesContact: Patrick M. Reagan (principal investigator)Taking people
  • Highlands Oncology Group - RogersRogers, United StatesContact: Joseph T. Beck (principal investigator)Taking people
  • Dartmouth Cancer Center - NorthSaint Johnsbury, United StatesContact: Charles Gaulin (principal investigator)Taking people
  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • UCSF Medical Center-ParnassusSan Francisco, United StatesContact: Madhav R. Seshadri (principal investigator)Taking people
  • Swedish Medical Center-First HillSeattle, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • Prisma Health Cancer Institute - SenecaSeneca, United StatesContact: Suzanne R. Fanning (principal investigator)Taking people
  • Henry Ford Health Providence Southfield HospitalSouthfield, United StatesContact: Erin RogersNo longer taking part
  • Highlands Oncology GroupSpringdale, United StatesContact: Joseph T. Beck (principal investigator)Taking people
  • Munson Medical CenterTraverse City, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Banner University Medical Center - TucsonTucson, United StatesContact: Muhammad Husnain (principal investigator)Taking people
  • University of Arizona Cancer Center-North CampusTucson, United StatesContact: Muhammad Husnain (principal investigator)Taking people
  • Saint Luke's Cancer Institute - Twin FallsTwin Falls, United StatesContact: Charles W. Drescher (principal investigator)Taking people
  • Wilmot Cancer Institute at WebsterWebster, United StatesContact: Patrick M. Reagan (principal investigator)Taking people
  • Henry Ford West Bloomfield HospitalWest Bloomfield, United StatesContact: Philip Kuriakose (principal investigator)Taking people
  • University of Kansas Hospital-Westwood Cancer CenterWestwood, United StatesContact: Marc S. Hoffmann (principal investigator)Taking people
  • Geisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre, United StatesContact: Joseph P. Lynch (principal investigator)Taking people
  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: Rakhee Vaidya (principal investigator)Taking people
  • Henry Ford Wyandotte HospitalWyandotte, United StatesContact: Philip Kuriakose (principal investigator)Taking people
  • University of Michigan Health - WestWyoming, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people

About the trial

What the trial wants to find out

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a drug called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, and delivers vedotin to kill them. Chemotherapy drugs, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving mosunetuzumab and/or polatuzumab vedotin after chemotherapy and CAR T-cell therapy may be more effective at controlling or shrinking the cancer than not giving them.

The 5 groups in the trial

  • Step I (lymphodepleting chemotherapy)Treatment being tested

    Patients receive lymphodepleting chemotherapy consisting of fludarabine IV and cyclophosphamide IV on study. Patients then receive tisagenlecleucel IV, axicabtagene ciloleucel IV, or lisocabtagene maraleucel IV on study.

    Treatment: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Positron Emission Tomography, and Tisagenlecleucel

  • Step II Arm I (mosunetuzumab)Treatment being tested

    Patients receive mosunetuzumab IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.

    Treatment: Biospecimen Collection, Computed Tomography, Mosunetuzumab, and Positron Emission Tomography

  • Step II Arm II (polatuzumab vedotin)Treatment being tested

    Patients receive polatuzumab vedotin IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.

    Treatment: Biospecimen Collection, Computed Tomography, Polatuzumab Vedotin, and Positron Emission Tomography

  • Step II Arm III (polatuzumab vedotin, mosunetuzumab)Treatment being tested

    Patients receive polatuzumab vedotin IV and mosunetuzumab IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.

    Treatment: Biospecimen Collection, Computed Tomography, Mosunetuzumab, Polatuzumab Vedotin, and Positron Emission Tomography

  • Step II Arm IV (observation)Existing treatment, for comparison

    Patients undergo observation on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study. Patients with subsequent progression within 12 months of CAR T-cell therapy may crossover to Arm III.

    Treatment: Biospecimen Collection, Computed Tomography, Patient Observation, and Positron Emission Tomography

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Plain-language title
Testing Drug Treatments After CAR T-cell Therapy for LymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 October 2026